Original article:
GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis
Although not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogues have shown efficacy and have been offered to owners of cats with FIP in our clinic since January 2020. The aim of this study was to examine the outcomes in cats with FIP who received GS-441524 or molnupiravir. The diagnosis of FIP was based on clinical signs, laboratory test results, and the presence of feline coronavirus RNA in blood or exudate. After providing oral and written information, owners of cats with a presumptive diagnosis of FIP were offered antiviral treatment with commercially available GS-441524 starting in June 2020 and with either GS-441524 or molnupiravir starting in January 2022. Dosage was 12.5–25 mg/kg/day for GS-441524 and 20–40 mg/kg/day for molnupiravir, depending on the presence of effusion and neurological and/or ocular signs, and continued for 84 days. A total of 118 cats with FIP (76 with effusion), 59 with GS-4421524 and 59 with molnupiravir were treated. Twenty cats died, 12/59 (20.3 %) in the GS-441524 group and 8/59 (13.6 %) in the molnupiravir group (p = 0.326), with the majority of deaths occurring within the first 10 days of treatment initiation. In the survivors, neurological and ocular signs resolved in all but one cat that had persistent seizures. Of the cats that completed treatment, 48/48 in the GS-441524 group and 51/52 in the molnupiravir group achieved remission. Laboratory parameters normalized within 6 to 7 weeks of drug initiation. Adverse events, such as liver function abnormalities, were transient and resolved without specific intervention. Our data suggest that GS-441524 and molnupiravir have similar efficacy and safety profiles in cats with FIP.
The full article can be found in English at https://doi.org/10.3389/fvets.2024.1422408
EN 
SK